Intuitive Surgical, Inc. (ISRG) Stock Analysis

Headquartered in Sunnyvale, California, Intuitive Surgical operates in the healthcare sector’s medical instruments and supplies industry as the pioneer of robotic-assisted surgery. The company builds and sells the multi-port da Vinci surgical system and the Ion endoluminal platform for minimally invasive lung biopsies. Its primary buyers are hospitals and healthcare systems, which purchase both the robotic hardware and a continuous stream of specialized stapling tools, energy instruments, and digital software services. Intuitive sells these platforms through direct capital and clinical sales teams while securing long-term maintenance and 24/7 technical support contracts.

Intuitive is the undisputed market leader in soft-tissue robotic surgery, controlling an estimated 60% or more of the global market. Its real economic moat is a razor-and-blade model where recurring revenue from instruments, accessories, and servicing accounts for roughly 85% of total sales. While rivals like Medtronic with its Hugo system and Johnson & Johnson with Ottava want a piece of this market, displacing Intuitive is tough because thousands of surgeons are already trained exclusively on da Vinci workflows. The main threat to watch is not overnight disruption, but pricing pressure as modular competitors target cost-conscious hospitals.

The business is in clear expansion mode, generating $8.35 billion in revenue for 2024, a 17% increase over 2023. Demand is backed by core procedure volume, with worldwide da Vinci procedures growing 18% year-over-year in the fourth quarter of 2024. The company expanded its global installed base by 15% to 9,902 systems by year-end 2024, placing 1,526 systems during the year. The commercial rollout of the next-generation da Vinci 5 platform is the primary growth catalyst, keeping hospital upgrade cycles active and cementing Intuitive’s market lead.